Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,637 | -2,848 | -1,640 | -969 | -547 |
| Accounts receivable | -333 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -1,008 | -247 | 1,047 | -211 | -256 |
| Other Working Capital | -2,159 | -465 | 408 | 76 | -76 |
| Other Operating Activity | 2,203 | 2,431 | 2 | 846 | 624 |
| Operating Cash Flow | $-3,934 | $-1,129 | $-183 | $-258 | $-255 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $0 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 273 | 273 | 273 | 245 |
| Debt Repayment | -410 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | 14,792 | 5 | 5 | 5 |
| Other Financing Activity | 0 | 0 | -97 | -30 | 0 |
| Financing Cash Flow | $-410 | $15,064 | $181 | $248 | $250 |
| Beginning Cash Position | 13,954 | 19 | 19 | 19 | 19 |
| End Cash Position | 9,610 | 13,954 | 16 | 8 | 13 |
| Net Cash Flow | $-4,344 | $13,935 | $-2 | $-11 | $-5 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,934 | -1,129 | -183 | -258 | -255 |
| Free Cash Flow | -3,934 | -1,129 | -183 | -258 | -255 |